Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
This study has been completed.
First Posted: February 23, 2012
Last Update Posted: January 5, 2016
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )